Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Mar 1, 2023

Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSIA, Pa., March 1, 2023...

Read more news from CSL

Recent News Releases
Sep 26, 2022

CSL Behring K.K. (Head Office: Minato-ku, Tokyo; President and Representative Director: Jean-Marc Morange) announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert® S.C. Injection 2000,” a lyophilized human C1-esterase inhibitor concentrate...

Read more news from CSL Behring

Recent News Releases
Mar 1, 2023

Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...

Read more news from CSL Seqirus

Recent News Releases
Feb 6, 2023

First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease

Read more news from CSL Vifor

Read all company news releases

Media Contacts

CSL 
Victoria, Australia
Phone: +61 0450 909 211
Email: media@csl.com.au

CSL Behring
North America
Email: MediaNorthAmerica@cslbehring.com

Europe
Email: MediaEurope@cslbehring.com

Asia Pacific
Email: MediaAsiaPacific@cslbehring.com

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496
Email: Emmanuella.Dekonor@seqirus.com

North America
Tiffany Cody
Phone: +1 908 370 1863
Email: Tiffany.Cody@seqirus.com

Asia Pacific
Hamish Walsh
Phone: 0422 424 338
Email: Hamish.Walsh@seqirus.com

CSL Plasma
United States
Plasma.Communications@CSLPLASMA.COM

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • instagram icon
  • facebook icon
Get our latest news releases in your inbox
* Required Fields